[Study of the incidence of invasive XXXX in neonates and childre aged less than 5 years in the Basque country and Navarre (Spain)].

@entity1 @entity1143 @entity66 @entity55 @entity114 @entity2260 @entity693 @entity3524 @entity328 @entity2259
BACKGROUND: @entity328 is the most commonly reported bacterial cause of @entity2259 and bacteremic @entity55 and the second most frequent cause of @entity693 . OBJECTIVE: To establish the incidence, characteristics and serotypes causing invasive @entity66 in @entity1 aged less than 5 years in two Autonomous Communities in Spain, the Basque country and Navarre, between 31 May 1988 and 1 June 2001. @entity1 AND METHODS: We performed a descriptive, observational and retrospective study. The study population was composed of @entity1 diagnosed with invasive @entity66 in the public and private hospitals with a pediatrics departments. Invasive @entity66 was defined as isolation of @entity2260 in blood, cerebrospinal fluid or any other sterile biological fluid. Medical records were reviewed and demographic and diagnostic variables were analyzed. Age-adjusted frequency rates were established for both regions using direct standardization. Confidence intervals were obtained by Poisson distribution. SPSS for Windows 10.0 and Epidat 2.1 were used for the analysis. Data were obtained from the 1999 municipal population census. RESULTS: One hundred seventy-one @entity1 aged 0-5 years were included. A total of 40.9 % (70 @entity1 ) were aged less than 12 months and 68.4 % were aged 0-2 years; 16.4 % had received drug therapy before diagnosis. The most common forms of presentation @entity2259 (45.6 %), bacteremic @entity55 (27.5 %) and @entity693 (14.6 %). The most frequent complications involved the respiratory tract, with @entity1143 in 23 % of cases of @entity55 . The standardized annual incidence rate of invasive @entity66 (cases per 100,000) in @entity1 aged 0-59 months was 58.82 (95 % CI: 27.99-89.65) in Navarre and 55.35 (95 % CI: 38.81-71.88) in the Basque Country. In @entity1 aged 0-23 months, the overall incidence was 93.49 cases per 100,000 @entity1 (95 % CI: 77.32-112.04) and in @entity1 aged 0-11 months, it was 110,21 cases per 100,000 @entity1 (95 % CI: 85.91-139.24). The incidence rates for @entity693 and @entity2259 in @entity1 aged 0-23 months was 15.98 (95 % CI: 9.76-24.68) and 51.14 (95 % IC: 39.38-65.30) cases per 100.000 @entity1 . Fifty-nine strains were serotyped. The most frequent serotypes/groups were 1, 4, 6B, 14, 18C, 19 and 23F. A total of 52.15 % of the serotypes were @entity114 -susceptible and 93 % were @entity3524 -susceptible. The serotypes/groups with the highest rates of resistance were 6B, 14,19, 23F and 35. CONCLUSION: Our incidence rates are similar to those observed in other countries such as the United States and are higher than those reported for the rest of Europe. Vaccine coverage is similar to that described in other articles.
